127 related articles for article (PubMed ID: 35569516)
1. Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use.
Creinin MD; Schreiber CA; Turok DK; Cwiak C; Chen BA; Olariu AI
Am J Obstet Gynecol; 2022 Dec; 227(6):871.e1-871.e7. PubMed ID: 35569516
[TBL] [Abstract][Full Text] [Related]
2. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
Eisenberg DL; Schreiber CA; Turok DK; Teal SB; Westhoff CL; Creinin MD;
Contraception; 2015 Jul; 92(1):10-6. PubMed ID: 25934164
[TBL] [Abstract][Full Text] [Related]
3. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial.
Jensen JT; Lukkari-Lax E; Schulze A; Wahdan Y; Serrani M; Kroll R
Am J Obstet Gynecol; 2022 Dec; 227(6):873.e1-873.e12. PubMed ID: 36096186
[TBL] [Abstract][Full Text] [Related]
4. Bleeding patterns for the Liletta
Schreiber CA; Teal SB; Blumenthal PD; Keder LM; Olariu AI; Creinin MD
Eur J Contracept Reprod Health Care; 2018 Apr; 23(2):116-120. PubMed ID: 29560743
[TBL] [Abstract][Full Text] [Related]
5. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use.
Darney PD; Stuart GS; Thomas MA; Cwiak C; Olariu A; Creinin MD
Contraception; 2018 Mar; 97(3):210-214. PubMed ID: 29038072
[TBL] [Abstract][Full Text] [Related]
6. Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding.
Chen BA; Eisenberg DL; Schreiber CA; Turok DK; Olariu AI; Creinin MD
Am J Obstet Gynecol; 2020 Apr; 222(4S):S888.e1-S888.e6. PubMed ID: 31866516
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System.
Teal SB; Turok DK; Chen BA; Kimble T; Olariu AI; Creinin MD
Obstet Gynecol; 2019 Jan; 133(1):63-70. PubMed ID: 30531565
[TBL] [Abstract][Full Text] [Related]
8. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
9. Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system.
Westhoff CL; Keder LM; Gangestad A; Teal SB; Olariu AI; Creinin MD
Contraception; 2020 Mar; 101(3):159-161. PubMed ID: 31786203
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
[TBL] [Abstract][Full Text] [Related]
11. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement.
Turok DK; Eisenberg DL; Teal SB; Keder LM; Creinin MD
Am J Obstet Gynecol; 2016 Nov; 215(5):599.e1-599.e6. PubMed ID: 27180886
[TBL] [Abstract][Full Text] [Related]
12. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
14. One-year pregnancy and continuation rates after placement of levonorgestrel or copper intrauterine devices for emergency contraception: a randomized controlled trial.
Kaiser JE; Turok DK; Gero A; Gawron LM; Simmons RG; Sanders JN
Am J Obstet Gynecol; 2023 Apr; 228(4):438.e1-438.e10. PubMed ID: 36427600
[TBL] [Abstract][Full Text] [Related]
15. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
[TBL] [Abstract][Full Text] [Related]
16. Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis.
Eggebroten JL; Sanders JN; Turok DK
Am J Obstet Gynecol; 2017 Jul; 217(1):51.e1-51.e7. PubMed ID: 28342716
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of low-dose levonorgestrel-releasing intrauterine system in Chinese women: a multicenter, single-arm, open labeled interventional trial].
Qian CF; Fan GS; Liao QP; Wu SY; La DD; Di W; Dong BH; Liu HW; Tang LD; Xiong ZA; Zhang HW; Hu YL; Yang NM; Ren ML; Shi H; Deng GP; Huang ZR
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):409-413. PubMed ID: 29961284
[No Abstract] [Full Text] [Related]
18. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
[TBL] [Abstract][Full Text] [Related]
19. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
20. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.
Nelson A; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Gemzell-Danielsson K
Obstet Gynecol; 2013 Dec; 122(6):1205-13. PubMed ID: 24240244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
